EEC 2026 | Poster P0311 | Author Interview

Vyas K, et al.

Disclaimer:

The views expressed in this interview do not reflect those of Jazz Pharmaceuticals and are solely intended to provide clinical insights from Dr Lattanzi reflective of her individual experience and expertise. Nothing in this presentation represents official Jazz policy or procedures and no proprietary or company confidential information is included.

For more information, please contact Medical Information ([email protected]) and provide your name and specialty in the e-mail text.

Epidyolex^® is approved in the EU for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, in patients ≥2 years of age; it is additionally approved in the EU for the adjunctive treatment of seizures associated with tuberous sclerosis complex in patients ≥2 years of age.